PIERIS PHARMACEUTICALS
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need. Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.
PIERIS PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2001-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.pieris.com
Total Employee:
101+
Status:
Active
Contact:
+118572468998
Email Addresses:
[email protected]
Total Funding:
160 M USD
Technology used in webpage:
Domain Not Resolving Google Maps HSTS Organization Schema Google Adsense Place Schema JobPosting Schema Amazon Singapore Region Colt
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
KBP Biosciences
A multinational clinical stage biotechnology company.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage pharmaceutical company developing innovative therapies.
Selecta Biosciences
Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Seagen
Seagen investment in Post-IPO Equity - Pieris Pharmaceuticals
Aquilo Capital Management
Aquilo Capital Management investment in Post-IPO Equity - Pieris Pharmaceuticals
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Pieris Pharmaceuticals
Surveyor Capital
Surveyor Capital investment in Post-IPO Equity - Pieris Pharmaceuticals
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Pieris Pharmaceuticals
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Pieris Pharmaceuticals
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Pieris Pharmaceuticals
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Pieris Pharmaceuticals
Montrose Capital Partners
Montrose Capital Partners investment in Post-IPO Equity - Pieris Pharmaceuticals
Lombard Odier
Lombard Odier investment in Post-IPO Equity - Pieris Pharmaceuticals
Key Employee Changes
Official Site Inspections
http://www.pieris.com Semrush global rank: 7.37 M Semrush visits lastest month: 801
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Pieris Pharmaceuticals"
Org Chart Pieris Pharmaceuticals - The Official Board
Organizational Chart of Pieris Pharmaceuticals. Pieris Pharmaceuticals www.pieris.com. has 12 executives +1 857 246 8998; Add an executive. Pieris Pharmaceuticals (PIRS) News . …See details»
Company Information :: Pieris Pharmaceuticals, Inc. (PIRS)
Company Contact Pieris Pharmaceuticals, Inc. 225 Franklin St., Floor 26 Boston, MA 02110 USA T: +1-857-246-8998See details»
Pieris Pharmaceuticals - The Org
Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way.See details»
Board Committees :: Pieris Pharmaceuticals, Inc. (PIRS)
In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on …See details»
Pieris Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Pieris Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Number of Board Member and Advisor …See details»
Pieris Pharmaceuticals - Overview, News & Similar companies
May 22, 2024 Pieris Pharmaceuticals contact info: Phone number: (857) 246-8998 Website: www.pieris.com What does Pieris Pharmaceuticals do? Founded in 2000 and headquartered …See details»
Pieris Pharmaceuticals - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
FAQ :: Pieris Pharmaceuticals, Inc. (PIRS)
Who are Pieris' independent auditors? Ernst & Young LLP. Who is Pieris' outside legal counsel? Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 …See details»
Pieris Pharmaceuticals Information - RocketReach
Pieris is a biotechnology company based in Boston, Massachusetts that could potentially be entitled to receive development, regulatory, and sales-based milestones from its 4-1BB …See details»
Pieris Pharmaceuticals - Craft
Oct 29, 2024 Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's …See details»
Pieris AG - Drug pipelines, Patents, Clinical trials - Synapse - Patsnap
Explore Pieris AG with its drug pipeline, therapeutic area, technology platform, 26 news, Disease Domain:Neoplasms, Technology Platform:Small molecule drug, Radiopharmaceuticals and …See details»
Pieris Pharmaceuticals Provides Strategic Update and Announces ...
Jul 18, 2023 Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology …See details»
Pieris AG - Crunchbase Company Profile & Funding
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The …See details»
Pieris Pharmaceuticals Announces Leadership Update
BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its …See details»
Pieris Pharma (PIRS) Provides Strategic Update and Announces …
Jul 18, 2023 Pieris' management and board of directors have assessed several strategic options, which will include focusing on execution of new or expanded partnerships to advance …See details»
Careers :: Pieris Pharmaceuticals, Inc. (PIRS)
In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on …See details»
Partnering :: Pieris Pharmaceuticals, Inc. (PIRS)
In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused on …See details»
Pieris Pharmaceuticals Provides Strategic Update and Announces ...
Jul 18, 2023 In December 2024, Pieris Pharmaceuticals merged with Palvella Therapeutics, Inc. Palvella Therapeutics (Nasdaq: PVLA), is a clinical-stage biopharmaceutical company focused …See details»
Pieris Pharmaceuticals Reports Third Quarter 2019 Financial …
Nov 11, 2019 BOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel …See details»